血友病治療市場:タイプ別(血友病A、血友病B)、薬物療法別(遺伝子組換え凝固因子濃縮療法、血漿由来凝固因子濃縮療法、非因子補充療法、その他)。世界の機会分析および産業予測、2021-2031年Hemophilia Treatment Market By Type (Hemophilia A, Hemophilia B), By Drug Therapy (Recombinant coagulation factor concentrates therapy, Plasma derived coagulation factor concentrates therapy, Non-factor replacement therapy, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031 世界の血友病治療市場は、2021年に127億6480万ドルと評価され、2031年には269億520万ドルに達すると予測され、2022年から2031年までのCAGRは7.5%を記録しています。 血友病は通常、遺伝性の出血性疾患で、血液が... もっと見る
日本語のページは自動翻訳を利用し作成しています。
サマリー世界の血友病治療市場は、2021年に127億6480万ドルと評価され、2031年には269億520万ドルに達すると予測され、2022年から2031年までのCAGRは7.5%を記録しています。血友病は通常、遺伝性の出血性疾患で、血液が適切に凝固しない病気です。このため、怪我や手術に続いて、自然出血を起こすことがあります。血液には凝固因子と呼ばれるタンパク質が多く含まれており、この凝固因子が出血を止めるのに役立ちます。血友病の人は、第VIII因子または第IX因子の濃度が低い。血友病の重症度は、血液中の因子の量によって決定されます。血友病は、血栓を形成するために必要な凝固因子タンパク質を作るための指示を提供する遺伝子の1つで、突然変異または変化によって引き起こされます。血友病には、血友病Aと血友病Bの2種類があります。血友病の治療には、血液が適切に凝固できるように、不足している血液凝固因子を補充することが含まれます。これは、市販の濃縮因子を静脈から投与する点滴によって行われます。血友病の患者さんは、自分で輸液を行う方法を学ぶことで、出血を止めることができ、定期的に輸液を行うことで、ほとんどの出血を防ぐことも可能です。 世界の血友病治療市場の成長を促進する主な要因としては、血友病の有病率の増加、血友病治療の技術的進歩、血友病管理に対する政府の有利な措置などが挙げられます。また、対象人口の増加、診断率の向上、血友病の予防的治療の増加も市場成長の推進要因となっています。しかし、血友病治療の高コスト、血友病の医薬品の不足、血漿由来製品に関連する重篤な副作用は、市場成長を制限すると予想されます。逆に、発展途上国における血友病に関する認知度の向上は、市場成長のための有利な機会を提供します。 血友病治療市場は、タイプ、薬物療法、地域に基づいて区分されています。タイプ別では、血友病Aと血友病Bに、薬物療法別では、遺伝子組換え凝固因子濃縮療法、血漿由来凝固因子濃縮療法、非因子補充療法、その他に市場が二分されます。地域別では、北米、欧州、アジア太平洋地域、LAMEAで分析されています。 本レポートに掲載されている主要企業は、Bayer AG、Pfizer, Inc.、F. Hoffmann-La Roche AG、CSL Ltd.、武田薬品工業株式会社、Novo Nordisk A/S、Grifols S.A.、スウェーデン孤児Biovitrium AB、Octapharma AGおよびMedexus Pharmaceuticals Inc.です。 ステークホルダーにとっての主なメリット ●本レポートは、2021年から2031年までの血友病治療市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、血友病治療市場の優勢な機会を特定します。 ●市場調査は、主要な推進要因、阻害要因、機会に関連する情報とともに提供されます。 ポーターのファイブフォース分析では、買い手と供給者の力関係を明らかにし、利害関係者が利益重視のビジネス決定を下し、供給者と買い手のネットワークを強化できるようにします。 血友病治療市場のセグメンテーションを詳細に分析することで、市場機会を決定することができます。 血友病治療市場に関する詳細な分析は、市場機会を決定するのに役立ちます。 市場プレイヤーのポジショニングは、ベンチマークを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。 地域別および世界別の血友病治療市場動向、キープレイヤー、市場セグメント、応用分野、市場成長戦略などの分析が含まれています。 主な市場セグメント タイプ別 血友病A 血友病B 薬物療法別 遺伝子組換え凝固因子製剤療法 血漿由来凝固因子製剤療法 非因子補充療法 非因子補充療法 ● その他 地域別 北米 米国 カナダ メキシコ 欧州 ドイツ フランス イギリス イタリア スペイン その他の地域 アジア・パシフィック 日本 中国 オーストラリア インド 韓国 その他のアジア太平洋地域 LAMEA ブラジル ○ 南アフリカ サウジアラビア LAMEAの他の地域 主な市場参加者 バイエル CSL Ltd.(CSLベーリング) F. ホフマン・ラ・ロシュ社 グリフォルス S.A メデクサス・ファーマシューティカルズ・インク(Medexus Pharmaceuticals Inc. ○ ノボ ノルディスク A/S オクタファーマAG Pfizer Inc. スウェーデン オーファン バイオビトラム AB 武田薬品工業(株) 目次CHAPTER 1:INTRODUCTION1.1.Report description 1.2.Key market segments 1.3.Key benefits to the stakeholders 1.4.Research Methodology 1.4.1.Secondary research 1.4.2.Primary research 1.4.3.Analyst tools and models CHAPTER 2:EXECUTIVE SUMMARY 2.1.Key findings of the study 2.2.CXO Perspective CHAPTER 3:MARKET OVERVIEW 3.1.Market definition and scope 3.2.Key findings 3.2.1.Top investment pockets 3.3.Porter’s five forces analysis 3.4.Top player positioning 3.5.Market dynamics 3.5.1.Drivers 3.5.2.Restraints 3.5.3.Opportunities 3.6.COVID-19 Impact Analysis on the market CHAPTER 4: HEMOPHILIA TREATMENT MARKET, BY TYPE 4.1 Overview 4.1.1 Market size and forecast 4.2 Hemophilia A 4.2.1 Key market trends, growth factors and opportunities 4.2.2 Market size and forecast, by region 4.2.3 Market analysis by country 4.3 Hemophilia B 4.3.1 Key market trends, growth factors and opportunities 4.3.2 Market size and forecast, by region 4.3.3 Market analysis by country CHAPTER 5: HEMOPHILIA TREATMENT MARKET, BY DRUG THERAPY 5.1 Overview 5.1.1 Market size and forecast 5.2 Recombinant coagulation factor concentrates therapy 5.2.1 Key market trends, growth factors and opportunities 5.2.2 Market size and forecast, by region 5.2.3 Market analysis by country 5.3 Plasma derived coagulation factor concentrates therapy 5.3.1 Key market trends, growth factors and opportunities 5.3.2 Market size and forecast, by region 5.3.3 Market analysis by country 5.4 Non-factor replacement therapy 5.4.1 Key market trends, growth factors and opportunities 5.4.2 Market size and forecast, by region 5.4.3 Market analysis by country 5.5 Others 5.5.1 Key market trends, growth factors and opportunities 5.5.2 Market size and forecast, by region 5.5.3 Market analysis by country CHAPTER 6: HEMOPHILIA TREATMENT MARKET, BY REGION 6.1 Overview 6.1.1 Market size and forecast 6.2 North America 6.2.1 Key trends and opportunities 6.2.2 North America Market size and forecast, by Type 6.2.3 North America Market size and forecast, by Drug Therapy 6.2.4 North America Market size and forecast, by country 6.2.4.1 U.S. 6.2.4.1.1 Market size and forecast, by Type 6.2.4.1.2 Market size and forecast, by Drug Therapy 6.2.4.2 Canada 6.2.4.2.1 Market size and forecast, by Type 6.2.4.2.2 Market size and forecast, by Drug Therapy 6.2.4.3 Mexico 6.2.4.3.1 Market size and forecast, by Type 6.2.4.3.2 Market size and forecast, by Drug Therapy 6.3 Europe 6.3.1 Key trends and opportunities 6.3.2 Europe Market size and forecast, by Type 6.3.3 Europe Market size and forecast, by Drug Therapy 6.3.4 Europe Market size and forecast, by country 6.3.4.1 Germany 6.3.4.1.1 Market size and forecast, by Type 6.3.4.1.2 Market size and forecast, by Drug Therapy 6.3.4.2 France 6.3.4.2.1 Market size and forecast, by Type 6.3.4.2.2 Market size and forecast, by Drug Therapy 6.3.4.3 U.K. 6.3.4.3.1 Market size and forecast, by Type 6.3.4.3.2 Market size and forecast, by Drug Therapy 6.3.4.4 Italy 6.3.4.4.1 Market size and forecast, by Type 6.3.4.4.2 Market size and forecast, by Drug Therapy 6.3.4.5 Spain 6.3.4.5.1 Market size and forecast, by Type 6.3.4.5.2 Market size and forecast, by Drug Therapy 6.3.4.6 Rest of Europe 6.3.4.6.1 Market size and forecast, by Type 6.3.4.6.2 Market size and forecast, by Drug Therapy 6.4 Asia-Pacific 6.4.1 Key trends and opportunities 6.4.2 Asia-Pacific Market size and forecast, by Type 6.4.3 Asia-Pacific Market size and forecast, by Drug Therapy 6.4.4 Asia-Pacific Market size and forecast, by country 6.4.4.1 Japan 6.4.4.1.1 Market size and forecast, by Type 6.4.4.1.2 Market size and forecast, by Drug Therapy 6.4.4.2 China 6.4.4.2.1 Market size and forecast, by Type 6.4.4.2.2 Market size and forecast, by Drug Therapy 6.4.4.3 Australia 6.4.4.3.1 Market size and forecast, by Type 6.4.4.3.2 Market size and forecast, by Drug Therapy 6.4.4.4 India 6.4.4.4.1 Market size and forecast, by Type 6.4.4.4.2 Market size and forecast, by Drug Therapy 6.4.4.5 South Korea 6.4.4.5.1 Market size and forecast, by Type 6.4.4.5.2 Market size and forecast, by Drug Therapy 6.4.4.6 Rest of Asia-Pacific 6.4.4.6.1 Market size and forecast, by Type 6.4.4.6.2 Market size and forecast, by Drug Therapy 6.5 LAMEA 6.5.1 Key trends and opportunities 6.5.2 LAMEA Market size and forecast, by Type 6.5.3 LAMEA Market size and forecast, by Drug Therapy 6.5.4 LAMEA Market size and forecast, by country 6.5.4.1 Brazil 6.5.4.1.1 Market size and forecast, by Type 6.5.4.1.2 Market size and forecast, by Drug Therapy 6.5.4.2 South Africa, 6.5.4.2.1 Market size and forecast, by Type 6.5.4.2.2 Market size and forecast, by Drug Therapy 6.5.4.3 Saudi Arabia 6.5.4.3.1 Market size and forecast, by Type 6.5.4.3.2 Market size and forecast, by Drug Therapy 6.5.4.4 Rest of LAMEA 6.5.4.4.1 Market size and forecast, by Type 6.5.4.4.2 Market size and forecast, by Drug Therapy CHAPTER 7: COMPANY LANDSCAPE 7.1. Introduction 7.2. Top winning strategies 7.3. Product Mapping of Top 10 Player 7.4. Competitive Dashboard 7.5. Competitive Heatmap 7.6. Key developments CHAPTER 8: COMPANY PROFILES 8.1 Bayer AG 8.1.1 Company overview 8.1.2 Company snapshot 8.1.3 Operating business segments 8.1.4 Product portfolio 8.1.5 Business performance 8.1.6 Key strategic moves and developments 8.2 CSL Ltd. (CSL Behring) 8.2.1 Company overview 8.2.2 Company snapshot 8.2.3 Operating business segments 8.2.4 Product portfolio 8.2.5 Business performance 8.2.6 Key strategic moves and developments 8.3 F. Hoffmann-La Roche AG 8.3.1 Company overview 8.3.2 Company snapshot 8.3.3 Operating business segments 8.3.4 Product portfolio 8.3.5 Business performance 8.3.6 Key strategic moves and developments 8.4 Grifols, S.A 8.4.1 Company overview 8.4.2 Company snapshot 8.4.3 Operating business segments 8.4.4 Product portfolio 8.4.5 Business performance 8.4.6 Key strategic moves and developments 8.5 Medexus Pharmaceuticals Inc. 8.5.1 Company overview 8.5.2 Company snapshot 8.5.3 Operating business segments 8.5.4 Product portfolio 8.5.5 Business performance 8.5.6 Key strategic moves and developments 8.6 Novo Nordisk A/S 8.6.1 Company overview 8.6.2 Company snapshot 8.6.3 Operating business segments 8.6.4 Product portfolio 8.6.5 Business performance 8.6.6 Key strategic moves and developments 8.7 octapharma ag 8.7.1 Company overview 8.7.2 Company snapshot 8.7.3 Operating business segments 8.7.4 Product portfolio 8.7.5 Business performance 8.7.6 Key strategic moves and developments 8.8 Pfizer Inc. 8.8.1 Company overview 8.8.2 Company snapshot 8.8.3 Operating business segments 8.8.4 Product portfolio 8.8.5 Business performance 8.8.6 Key strategic moves and developments 8.9 Swedish Orphan Biovitrum AB 8.9.1 Company overview 8.9.2 Company snapshot 8.9.3 Operating business segments 8.9.4 Product portfolio 8.9.5 Business performance 8.9.6 Key strategic moves and developments 8.10 Takeda Pharmaceuticals Company ltd 8.10.1 Company overview 8.10.2 Company snapshot 8.10.3 Operating business segments 8.10.4 Product portfolio 8.10.5 Business performance 8.10.6 Key strategic moves and developments
SummaryThe global hemophilia treatment market was valued at $12,764.8 million in 2021, and is projected to reach $26,905.2 million by 2031, registering a CAGR of 7.5% from 2022 to 2031. Table of ContentsCHAPTER 1:INTRODUCTION1.1.Report description 1.2.Key market segments 1.3.Key benefits to the stakeholders 1.4.Research Methodology 1.4.1.Secondary research 1.4.2.Primary research 1.4.3.Analyst tools and models CHAPTER 2:EXECUTIVE SUMMARY 2.1.Key findings of the study 2.2.CXO Perspective CHAPTER 3:MARKET OVERVIEW 3.1.Market definition and scope 3.2.Key findings 3.2.1.Top investment pockets 3.3.Porter’s five forces analysis 3.4.Top player positioning 3.5.Market dynamics 3.5.1.Drivers 3.5.2.Restraints 3.5.3.Opportunities 3.6.COVID-19 Impact Analysis on the market CHAPTER 4: HEMOPHILIA TREATMENT MARKET, BY TYPE 4.1 Overview 4.1.1 Market size and forecast 4.2 Hemophilia A 4.2.1 Key market trends, growth factors and opportunities 4.2.2 Market size and forecast, by region 4.2.3 Market analysis by country 4.3 Hemophilia B 4.3.1 Key market trends, growth factors and opportunities 4.3.2 Market size and forecast, by region 4.3.3 Market analysis by country CHAPTER 5: HEMOPHILIA TREATMENT MARKET, BY DRUG THERAPY 5.1 Overview 5.1.1 Market size and forecast 5.2 Recombinant coagulation factor concentrates therapy 5.2.1 Key market trends, growth factors and opportunities 5.2.2 Market size and forecast, by region 5.2.3 Market analysis by country 5.3 Plasma derived coagulation factor concentrates therapy 5.3.1 Key market trends, growth factors and opportunities 5.3.2 Market size and forecast, by region 5.3.3 Market analysis by country 5.4 Non-factor replacement therapy 5.4.1 Key market trends, growth factors and opportunities 5.4.2 Market size and forecast, by region 5.4.3 Market analysis by country 5.5 Others 5.5.1 Key market trends, growth factors and opportunities 5.5.2 Market size and forecast, by region 5.5.3 Market analysis by country CHAPTER 6: HEMOPHILIA TREATMENT MARKET, BY REGION 6.1 Overview 6.1.1 Market size and forecast 6.2 North America 6.2.1 Key trends and opportunities 6.2.2 North America Market size and forecast, by Type 6.2.3 North America Market size and forecast, by Drug Therapy 6.2.4 North America Market size and forecast, by country 6.2.4.1 U.S. 6.2.4.1.1 Market size and forecast, by Type 6.2.4.1.2 Market size and forecast, by Drug Therapy 6.2.4.2 Canada 6.2.4.2.1 Market size and forecast, by Type 6.2.4.2.2 Market size and forecast, by Drug Therapy 6.2.4.3 Mexico 6.2.4.3.1 Market size and forecast, by Type 6.2.4.3.2 Market size and forecast, by Drug Therapy 6.3 Europe 6.3.1 Key trends and opportunities 6.3.2 Europe Market size and forecast, by Type 6.3.3 Europe Market size and forecast, by Drug Therapy 6.3.4 Europe Market size and forecast, by country 6.3.4.1 Germany 6.3.4.1.1 Market size and forecast, by Type 6.3.4.1.2 Market size and forecast, by Drug Therapy 6.3.4.2 France 6.3.4.2.1 Market size and forecast, by Type 6.3.4.2.2 Market size and forecast, by Drug Therapy 6.3.4.3 U.K. 6.3.4.3.1 Market size and forecast, by Type 6.3.4.3.2 Market size and forecast, by Drug Therapy 6.3.4.4 Italy 6.3.4.4.1 Market size and forecast, by Type 6.3.4.4.2 Market size and forecast, by Drug Therapy 6.3.4.5 Spain 6.3.4.5.1 Market size and forecast, by Type 6.3.4.5.2 Market size and forecast, by Drug Therapy 6.3.4.6 Rest of Europe 6.3.4.6.1 Market size and forecast, by Type 6.3.4.6.2 Market size and forecast, by Drug Therapy 6.4 Asia-Pacific 6.4.1 Key trends and opportunities 6.4.2 Asia-Pacific Market size and forecast, by Type 6.4.3 Asia-Pacific Market size and forecast, by Drug Therapy 6.4.4 Asia-Pacific Market size and forecast, by country 6.4.4.1 Japan 6.4.4.1.1 Market size and forecast, by Type 6.4.4.1.2 Market size and forecast, by Drug Therapy 6.4.4.2 China 6.4.4.2.1 Market size and forecast, by Type 6.4.4.2.2 Market size and forecast, by Drug Therapy 6.4.4.3 Australia 6.4.4.3.1 Market size and forecast, by Type 6.4.4.3.2 Market size and forecast, by Drug Therapy 6.4.4.4 India 6.4.4.4.1 Market size and forecast, by Type 6.4.4.4.2 Market size and forecast, by Drug Therapy 6.4.4.5 South Korea 6.4.4.5.1 Market size and forecast, by Type 6.4.4.5.2 Market size and forecast, by Drug Therapy 6.4.4.6 Rest of Asia-Pacific 6.4.4.6.1 Market size and forecast, by Type 6.4.4.6.2 Market size and forecast, by Drug Therapy 6.5 LAMEA 6.5.1 Key trends and opportunities 6.5.2 LAMEA Market size and forecast, by Type 6.5.3 LAMEA Market size and forecast, by Drug Therapy 6.5.4 LAMEA Market size and forecast, by country 6.5.4.1 Brazil 6.5.4.1.1 Market size and forecast, by Type 6.5.4.1.2 Market size and forecast, by Drug Therapy 6.5.4.2 South Africa, 6.5.4.2.1 Market size and forecast, by Type 6.5.4.2.2 Market size and forecast, by Drug Therapy 6.5.4.3 Saudi Arabia 6.5.4.3.1 Market size and forecast, by Type 6.5.4.3.2 Market size and forecast, by Drug Therapy 6.5.4.4 Rest of LAMEA 6.5.4.4.1 Market size and forecast, by Type 6.5.4.4.2 Market size and forecast, by Drug Therapy CHAPTER 7: COMPANY LANDSCAPE 7.1. Introduction 7.2. Top winning strategies 7.3. Product Mapping of Top 10 Player 7.4. Competitive Dashboard 7.5. Competitive Heatmap 7.6. Key developments CHAPTER 8: COMPANY PROFILES 8.1 Bayer AG 8.1.1 Company overview 8.1.2 Company snapshot 8.1.3 Operating business segments 8.1.4 Product portfolio 8.1.5 Business performance 8.1.6 Key strategic moves and developments 8.2 CSL Ltd. (CSL Behring) 8.2.1 Company overview 8.2.2 Company snapshot 8.2.3 Operating business segments 8.2.4 Product portfolio 8.2.5 Business performance 8.2.6 Key strategic moves and developments 8.3 F. Hoffmann-La Roche AG 8.3.1 Company overview 8.3.2 Company snapshot 8.3.3 Operating business segments 8.3.4 Product portfolio 8.3.5 Business performance 8.3.6 Key strategic moves and developments 8.4 Grifols, S.A 8.4.1 Company overview 8.4.2 Company snapshot 8.4.3 Operating business segments 8.4.4 Product portfolio 8.4.5 Business performance 8.4.6 Key strategic moves and developments 8.5 Medexus Pharmaceuticals Inc. 8.5.1 Company overview 8.5.2 Company snapshot 8.5.3 Operating business segments 8.5.4 Product portfolio 8.5.5 Business performance 8.5.6 Key strategic moves and developments 8.6 Novo Nordisk A/S 8.6.1 Company overview 8.6.2 Company snapshot 8.6.3 Operating business segments 8.6.4 Product portfolio 8.6.5 Business performance 8.6.6 Key strategic moves and developments 8.7 octapharma ag 8.7.1 Company overview 8.7.2 Company snapshot 8.7.3 Operating business segments 8.7.4 Product portfolio 8.7.5 Business performance 8.7.6 Key strategic moves and developments 8.8 Pfizer Inc. 8.8.1 Company overview 8.8.2 Company snapshot 8.8.3 Operating business segments 8.8.4 Product portfolio 8.8.5 Business performance 8.8.6 Key strategic moves and developments 8.9 Swedish Orphan Biovitrum AB 8.9.1 Company overview 8.9.2 Company snapshot 8.9.3 Operating business segments 8.9.4 Product portfolio 8.9.5 Business performance 8.9.6 Key strategic moves and developments 8.10 Takeda Pharmaceuticals Company ltd 8.10.1 Company overview 8.10.2 Company snapshot 8.10.3 Operating business segments 8.10.4 Product portfolio 8.10.5 Business performance 8.10.6 Key strategic moves and developments
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療)の最新刊レポート
Allied Market Research社のその他分野での最新刊レポート
本レポートと同じKEY WORD(coagulation factor)の最新刊レポート
よくあるご質問Allied Market Research社はどのような調査会社ですか?アライドマーケットリサーチ(Allied Market Research)は世界の多様な市場に関する戦略や将来推計、成長/衰退予測、機会分析、消費者調査などを行い、市場調査レポートを積極的に出版しています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/21 10:26 156.13 円 165.08 円 200.38 円 |